SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-21-023171
Filing Date
2021-09-20
Accepted
2021-09-20 17:21:12
Documents
15
Period of Report
2021-09-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 47000
2 ex5-1.htm EX-5.1 13908
3 ex10-1.htm EX-10.1 281224
  Complete submission text file 0001493152-21-023171.txt   629238

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lixt-20210920.xsd EX-101.SCH 3521
5 XBRL DEFINITION FILE lixt-20210920_def.xml EX-101.DEF 27689
6 XBRL LABEL FILE lixt-20210920_lab.xml EX-101.LAB 36678
7 XBRL PRESENTATION FILE lixt-20210920_pre.xml EX-101.PRE 26307
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5267
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 211264077
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences